Orange Book Blog: Federal Circuit Affirms Invalidity of AstraZeneca's Toprol-XL Patent

Orange Book Blog: Federal Circuit Affirms Invalidity of AstraZeneca's Toprol-XL Patent: "On Monday, the Federal Circuit affirmed a district court summary judgment decision that AstraZeneca's U.S. Patent No. 5,081,154 is invalid for double patenting. The '154 patent claims metoprolol succinate, the active ingredient in Astra's blockbuster cardiovascular drug Toprol-XL. KV Pharmaceutical, Andrx, and Eon Labs have all filed ANDAs for generic Toprol-XL and are defendants in the litigation."